Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Maintenance in mCRC (RE-SUSTAIN)
NCT05818267Unknown
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of regorafenib in colorectal cancer (metastatic) (mCRC). Primary endpoint: duration of disease control at 6 months. Status: unknown.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05818267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818267.